The primary outcome measures include disease-free survival (DFS) for patients with NSCLC with PD-L1 expression TC ≥25% and patients with NSCLC without EGFR mutations or ALK rearrangements. The gene discussed is ALK; the disease is non-small cell lung carcinoma.